Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe webpage has updated its version from v2.16.2 to v2.16.3 and has added several future dates while removing past dates.SummaryDifference0.5%
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check16 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check23 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check53 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check60 days agoChange DetectedThe webpage has been updated to include new information about a clinical study involving Urothelial Cancer, specifically detailing the drugs Carboplatin and Gemcitabine, and the involvement of collaborators like Merck Sharp & Dohme LLC and Seagen Inc. Additionally, the revision number has been updated to v2.15.0.SummaryDifference13%
Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.